What the trial was testing
The trial enrolled 40 patients with al amyloidosis. The study was sponsored by Columbia University and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
57% had a partial response or better in relapsed AL amyloidosis.
Journal of Clinical Oncology · 2020 · NCT01222260
These findings — that achieved partial response or better in relapsed AL amyloidosis on bendamustine + dex — were published in the Journal of Clinical Oncology and represent the headline result of the study.
Researchers tracked outcomes across 40 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with al amyloidosis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Bendamustine (Treanda) is FDA-approved for chronic lymphocytic leukemia and lymphoma but is used off-label for AL amyloidosis. The first-line FDA-approved option for AL amyloidosis now includes daratumumab combinations. Ask a hematologist with amyloidosis expertise about treatment.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open al amyloidosis trials
Registry of Older Patients With Cancer
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis. Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close to 60%. Considering that Bcl-2 inhibitor is effective for AL amyloidosis with t(11; 14) and the median hematologic onset time of DBD is 7 days. We design a a prospective study on AL amyloidosis with t(11; 14). All patients receive DBD at the beginning. Patient will receive DBD for at least 6 cycles if achieve rapid hematologic response at day 7, while other patients will receive daratumumab, venetoclax and dexamethasone.